Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label trial of immunomodulatory therapy stratified by IL-6 in severe COVID-19 pneumonia
2020-001437-12Phase 4Active
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Apr 2020
- Modality
- Small Molecules, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tocilizumab and cyclosporine in coronavirus disease 2019 (COVID-19) and viral pneumonia (3 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Mortality at day 28 after treatment initiation. Started Apr 2020; status: active.
02
Drugs
tocilizumabcyclosporine
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on 2020-001437-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001437-12.